Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Global Health Policy & Center for Global Development, London, UK.
J Comp Eff Res. 2020 Dec;9(18):1243-1246. doi: 10.2217/cer-2020-0174. Epub 2020 Dec 4.
The race to find an effective treatment for coronavirus disease 2019 (COVID-19) is still on, with only two treatment options currently authorized for emergency use and/or recommended for patients hospitalized with severe respiratory symptoms: low-dose dexamethasone and remdesivir. The USA decision to stockpile the latter has resulted in widespread condemnation and in similar action being taken by some other countries. In this commentary we discuss whether stockpiling remdesivir is justified in light of the currently available evidence.
寻找针对 2019 冠状病毒病（COVID-19）的有效治疗方法的竞赛仍在继续，目前仅有两种治疗方案获得紧急使用授权和/或推荐给患有严重呼吸道症状的住院患者使用：低剂量地塞米松和瑞德西韦。美国决定储备瑞德西韦，这招致了广泛的谴责，一些其他国家也采取了类似行动。在本评论中，我们根据现有证据讨论了储备瑞德西韦是否合理。
